Cn /En

Tumor vaccine


Welcome to learn about our tumor vaccine preclinical evaluation platform. Currently, there is a significant research gap in the preclinical evaluation of tumor vaccines. Traditional syngeneic models are limited in application due to the significant differences between the mouse immune system and that of humans. Although the CD34+ HSC humanized model has been humanized, the reconstruction of immune system cells is low and unstable. To better simulate and evaluate the effects of tumor vaccines, we provide a series of highly specializedmodels, successfully addressing these issues.
Platform Features and Applications:
iHuPBMC-OncVax tumor vaccine model: This model comprehensively constructs lymphocytes and myeloid cells, ensuring that antigens are effectively presented in vivo, thus providing a real and effective evaluation environment for tumor vaccines.
MHC humanized mouse model: We replace the MHC molecules of immunocompetent mice with human MHC molecules, making the antigen presentation in mice closer to the real situation in humans, thus providing a powerful tool for vaccine development and evaluation.
Our tumor vaccine preclinical evaluation platform provides strong support and tools for your research. If you have any questions or need further information, please feel free to Contact Us.